Biomarker Expression in Pelvic High-grade Serous Carcinoma: Comparison of Ovarian and Omental Sites
Biomarker Expression in Pelvic High-grade Serous Carcinoma: Comparison of Ovarian and Omental Sites
复制标题
DOI：
10.1097/pgp.0b013e31820d20ba
复制
发表时间：
2011-07-01
影响因子：
2.4
通讯作者：
Gilks, C. Blake
中科院分区：
文献类型：
--
作者：
Koebel, Martin;Turbin, Dmitry;Gilks, C. Blake
新辅助治疗在高分期卵巢癌的治疗中具有新兴的作用。一些卵巢癌亚型对标准化疗反应不佳，因此在开始治疗前进行准确的亚型诊断非常重要。这种诊断通常基于网膜活检标本。特别是，对于非常小的活检，可能需要诊断生物标志物的免疫染色。为了评估盆腔高级别浆液性癌中肿瘤内生物标志物表达的异质性，我们比较了卵巢和网膜部位之间10种生物标志物的表达。组织微阵列由123例高级别浆液性癌与配对的卵巢和网膜肿瘤样本构建。这些样品用已经用于卵巢癌亚型诊断的生物标志物（WT 1、TP 53/p53、MUC 16/CA 125、CDKN 2A/p16）以及肿瘤微环境的生物标志物（CD 8、CD 163、CD 4、PDGFRB）、细胞粘附（CDH 1/E-Cadherin）和增殖（Ki 67）染色。比较了来自2个位点的样品中的表达频率，以及个体肿瘤在2个位点的一致性。促结缔组织增生基质反应的两个标志物（PDGFRB、PDGFRB）在大网膜中的表达高于卵巢（P
Neoadjuvant therapy has an emerging role in the treatment of high-stage ovarian carcinoma. Some ovarian carcinoma subtypes do not respond well to standard chemotherapy, making accurate subtype diagnosis before starting therapy important. This diagnosis is frequently based on omental biopsy specimens. In particular, with very small biopsies, immunostaining for diagnostic biomarkers may be needed. To assess intratumoral heterogeneity of biomarker expression in pelvic high-grade serous carcinoma, we compared the expression of a set of 10 biomarkers between ovarian and omental sites. Tissue microarrays were constructed from 123 high-grade serous carcinomas with paired ovarian and omental tumor samples. These samples were stained with biomarkers that have been used in ovarian carcinoma subtype diagnosis (WT1, TP53/p53, MUC16/CA125, CDKN2A/p16), and with biomarkers of the tumor microenvironment (CD8, CD163, SPARC, PDGFRB), cell adhesion (CDH1/E-Cadherin), and proliferation (Ki67) as well. Expression frequencies in samples from the 2 sites were compared, as was concordance at the 2 sites for individual tumors. The 2 markers of desmoplastic stromal response (PDGFRB, SPARC) were more frequently expressed in the omentum compared with the ovary (P